Hyperleukocytosis (HL) per se is a laboratory abnormality, commonly defined by a white blood cell (WBC) count above 100,000/µL, caused by leukemic cell proliferation. Not the high blood count itself, but complications such as leukostasis, tumor lysis syndrome (TLS) and disseminated intravascular coagulation (DIC) put the patient at risk and require therapeutic intervention. The risk of complications is higher in acute than in chronic leukemias, and particularly leukostasis occurs more often in acute myeloid leukemia (AML) for several reasons. Only a small proportion of AML patients present with HL, but these patients have a particularly dismal prognosis due to i) a higher risk of early death resulting from HL complications and ii) a higher probability of relapse and death in the long run.
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Incidence and pathophysiology
In untreated AML, about 5 to 20% of patients present with HL. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 In a patient with HL, underlying diseases other than AML such as ALL, CLL and CML, particularly in acceleration or blast crisis, should be considered as differential diagnosis. In addition to classic cytology and flow-cytometric immunophenotyping, the rapid screening for the bcr-abl transcript by FISH or PCR is of importance for diagnostic certainty. Although commonly defined by WBC counts >100,000/µL, it should be noted that also WBC levels below this arbitrary threshold can cause HL related complications ( Figure 1 ). Retrospective analyses have revealed an association with monocytic AML subtypes (FAB M4/5) 11, 12, 9 , chromosomal MLL rearrangement 11q23 13, 9 and the FLT3-ITD mutation 14, 15, 9 , although only some patients with these characteristics actually develop HL. In a cohort of 3,510 newly diagnosed AML patients of the Study Alliance Leukemia study group (SAL), 357 patients (10%) had WBCs >100,000/µL at initial diagnosis. Our explorative analyses revealed 28% FAB M4/5 in HL patients as opposed to 16% in non-HL patients (comparison by Chi-squared test, p<0.001).
Further associations were seen regarding higher LDH (1,158 Ul/l versus 386 U/l; p<0.001), FLT3-ITD (45% versus 16%; p<0.001), NPM1 (44% versus 24%; p<0.001), but no association with MLL-PTD (2% versus 1%; p=1.0). The median ECOG performance status score at initial diagnosis was higher in HL patients and less patients displayed favorable or adverse cytogenetic aberrations (previously unpublished data).
Two main pathogenetic factors are responsible for the development of HL: first, a rapid blast proliferation leading to a high leukemic tumor burden; second, disruption in normal hematopoietic cell adhesion leading to a reduced affinity to the bone marrow. 16 The high number of leukocytes may cause three main complications: disseminated intravasal coagulation (DIC), tumor lysis syndrome (TLS) and leukostasis. DIC is caused by high cell turnover and associated high levels of released tissue factor which then triggers the extrinsic pathway via Factor VII. 17 TLS may occur as a result of spontaneous or treatment-induced cell death. Leukostasis is explained by two main mechanisms. The rheological model is based 4 
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How I treat hyperleukocytosis in AML on a mechanical disturbance in the blood flow by an increase of viscosity in the microcirculation. 18, 19 The fact that myeloid blasts are larger than immature lymphocytes or mature granulocytes and that leukemic blasts are considerably less deformable than mature leukocytes explains the higher incidence of leukostatic complications in AML as opposed to acute lymphoblastic leukemia, chronic myeloid leukemia or chronic lymphocytic leukemia. 20, 8, 21, 22 However, the observation that there is no clear correlation between the leukocyte count and the severity and frequency of leukostatic complications 6, 23, 24 point towards additional cellular mechanisms involved in the genesis of leukostasis such as interactions between leukemic cells and the endothelium, 25, 26 mediated by adhesion molecules. 27 Bug et al. described a significant association between expression of CD11c and a high risk of early death in leukocytosis; 28 Novotny et al. showed a correlation between expression of CD56/NCAM and development of leukostasis in patients with myelomonocytic subtypes of AML. 29 Stucki and co-workers observed a secretion of tumor necrosis factoralpha (TNF-α) and interleukin-1 beta (IL-1β) by leukemic myeloblasts leading to change in the make-up of adhesion molecules on the endothelial cells. Several molecules such as intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin were shown to be upregulated. By this mechanism, leukemic cells can promote their own adhesion to the endothelium and create a self-perpetuating loop in which more and more blast cells migrate and attach to the endothelium. 30 Additionally, cytokinedriven endothelial damage, subsequent hemorrhage, hypoxic damage and AML blast extravasation followed by consecutive tissue damage by matrix metalloproteases might contribute to the pathogenesis of leukostasis. 31, 32, 33, 34 Important mechanisms of leukostasis are shown in Figure 3 .
Clinical manifestations and treatment options
Leukostasis, DIC and TLS represent the three main clinical manifestations of HL which can cause life-threatening complications in AML patients. Early mortality in this patient group is higher than in AML without HL and ranges from 8% in the first 24 hours 9 to around 20% during the first week 9, 35, 36, 29 , the main causes of death being bleedings, thromboembolic events, neurological and pulmonary complications. In AML without HL, the early death rate is significantly lower, ranging around 3-9%. 37 But also in long-term follow-up, HL is a negative prognostic factor as indicated by significantly shorter overall survival (OS) 38 
Tumor lysis syndrome
Although TLS is more common in lymphoid malignancies and ALL, it can also occur in AML.
In patients with leukostasis, TLS occurs in up to 10% of cases. 20 There is no evidence that low-dose cytostatic treatment with a slow and gradual leukocyte reduction decreases the risk of tumor lysis as opposed to standard-dose intensive induction. 42 In patients with a curative treatment concept, intensive chemotherapy should therefore start immediately and without a "pre-phase". Prevention strategies include hydration and prophylactic allopurinol. Close monitoring during the first days of treatment will reveal tumor lysis characterized by elevation of serum potassium, phosphorus, uric acid levels and potentially by decline in calcium levels.
Hyperuricemia can lead to acute renal damage or even failure and should be treated with allopurinol or rasburicase depending on the uric acid levels. Established TLS is managed similarly, with the addition of aggressive hydration and diuresis, plus allopurinol or rasburicase for hyperuricemia. Additionally, electrolyte imbalances should be corrected.
Whereas allopurinol is the less expensive therapy for hyperuricemia, it only prevents the synthesis of new uric acid. In cases with marked hyperuricaemia and TLS, rasburicase (urate oxidase) effectively lowers uric acid levels by enzymatic degradation, even after a single and low-dose application. Figure 1) . 39, 48 The typical clinical symptoms of leukostasis are listed in Table 1 . Apart from tissue damage caused by stasis and leukocyte infiltration, hemorrhage and thromboembolic events are frequent and relevant complications of leukostasis. 39, 9, 18 Immediate initiation of cytoreductive treatment in this chemosensitive disease is mandatory and should not be delayed. 39, 50 In case that a rapid diagnosis cannot be made, the patient should be transferred to a specialized hospital on the same day. Whereas there are widely consented and accepted standards for the treatment of DIC and TLS, the use of leukapheresis in HL and the mode of cytoreduction is still a matter of debate.
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How I treat hyperleukocytosis in AML Cytoreduction Hydroxyurea (HU) is commonly used before a proper induction regimen is implemented in order to lower the tumor burden and reduce the risk of tumorlysis. However, there is no data indicating that this approach is superior to immediate induction or that tumorlysis can be prevented by a low-dose cytoreduction strategy. Results of a recent systematic review lack evidence for a superiority of this approach over standard-dose induction. 42 In all patients eligible for intensive curative treatment, standard-dose or high-dose cytarabine plus anthracyclin or mitoxantrone should be initiated as soon as the HL diagnosis is made. 51, 52 This applies to all HL patients with AML, both with and without signs of leukostasis. In cases with unclear HL, HU may be used short term as bridging strategy ( Figure 1 ). If respiratory failure develops despite falling WBC counts, pneumonia or cytarabine-induced pulmonary damage 53, 54 should be considered and treated accordingly. In acute promyelocytic leukemia (APL), treatment with ATRA should be initiated immediately, even if APL is only suspected.
After APL confirmation, idarubicin or arsenic trioxide (ATO) should be added for proper cytoreduction treatment. 55 
Leukapheresis
The term leukapheresis stems from the Greek to take away or remove. 39 Leukapheresis in HL is based on the principle to rapidly remove excessive leukocytes by mechanical separation. The mechanical removal of leukocytes by leukapheresis has become routinely available in many hematological treatment centers. If apheresis equipment is not available, judicious phlebotomies with concurrent blood and/or plasma replacement may be used as alternative strategy to reduce HL. 39 In modern apheresis devices (blood cell separators),
WBCs and their precursors are separated from patients' blood by centrifugation. During a single leukapheresis, the WBC count can be reduced by 10-70%. 56 The efficacy of leukapheresis to reduce the number of WBC has been shown in several clinical trials. comparison. The results of the trials could not be synthesized due to heterogeneity, but there was neither a trend for higher or lower early death in patients with and without leukapheresis nor did the early death rates differ depending on the leukapheresis strategy used (systematically versus occasionally versus not). In a comparison between institutions with leukapheresis in all HL patients and institutions using a "never" or "sometimes" policy, no beneficial effect could be shown. Similarly, the investigators of this comprehensive review did not observe an inverse relationship between the percentage of patients receiving a leukapheresis and the incidence of early death. 42 Pastore et al. analyzed a HL patient population based on a score correcting for disease-related risk factors in order to separate the leukapheresis effect on early death. According to their analysis, leukapheresis had no beneficial effect on early death, irrespective of the individual early death risk. 9 All trials where retrospective and not randomized and it is unlikely that such studies will ever be feasible given the rarity of the condition, urgency for decision making and strong physician preferences.
As part of a discussion, the efficient reduction of WBCs and the standardized and generally well tolerated procedure are brought forward as arguments for using leukapheresis whereas hypercalcemia, the use of anticoagulants, aggravation of pre-exisiting thrombopenia, 23 
Conclusion: How I treat HL in AML
Based on these facts and considerations, we follow the treatment algorithm shown in Figure   5 . In patients with AML and HL, we assess eligibility for intensive treatment. Treatmenteligible patients start with standard induction treatment combining standard-dose cytarabine plus daunorubicin (7+3). In parallel, we provide intravenous hydration to ensure adequate urine flow, we use allopurinol or rasburicase to reduce serum uric acid levels and check for signs of DIC or tumor lysis twice daily until the WBC has fallen below upper normal limits.
Patients with suspected APL should receive ATRA immediately and additionally idarubicin after cytologic or genetic APL confirmation. In addition to idarubicin, the WBC count is further Conflict-of-interest disclosure: The authors declare no competing financial interests.
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How I treat hyperleukocytosis in AML A 68-year old man sought medical help at the emergency unit of his local hospital because of weakness, bone pain and night sweats over several weeks. He was admitted because of HL of around 170,000/µL, anemia and thrombocytopenia. After the diagnosis of AML M4 was made, hydroxyurea and cytarabine were started and the patient was transferred to our hospital, presenting with a WBC count 70,000/µL and central neurological deficits with speech impairment. An MRI scan showed several meningeal lesions, but the cerebrospinal fluid (CSF) cell count was normal and infection parameters were negative. In order to avoid CSF contamination with leukemic blasts, lumbar puncture was postponed until peripheral blast clearance. We continued cytarabine induction and added daunorubicin for three days.
WBC counts declined rapidly after initiation of cytarabine; the patient's ability to speak improved gradually and a control MRI seven days after admission showed multiple hemorrhagic lesions, most pronounced in the hemispheres, with no signs of extramedullary leukemic lesions or meningeosis (A). In the consecutive aplasia, our patient developed E. Additional changes after cytokine-driven endothelial cell activation can be a loss of vascular integrity and modification of endothelial phenotype from antithrombotic to prothrombotic phenotype. 62, 63 Endothelial disintegration allows myeloblast migration and blood extravasation and microhemorrhages. Tissue invasion of myeloblasts is mediated by metalloproteinases (MMPs, particularly MMP-9) which are expressed on the cellular surface and secreted into the extracellular matrix. 34, 33, 31, 64 For personal use only. on October 31, 2017. by guest www.bloodjournal.org From 20 
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